Table 2

Clinical characteristics of nondiabetic study subjects

VariableNDC-leanNDC-owNDC-allIgAGN
N (male/female)219 (96/123)126 (81/45)*345 (177/168)98 (61/37)
Age (years)33 ± 1033 ± 933 ± 1052 ± 13*
BMI (kg/m2)22.2 ± 1.728.2 ± 2.8*24.3 ± 3.626.5 ± 4.3*
Waist (cm)
 Male85 (80–88)97 (92–102)89 (84–96)91 (87–100)
 Female76 (72–81)90 (86–98)*79 (74–85)80 (71–87)
Blood pressure (mmHg)
 Systolic123 ± 14130 ± 13*126 ± 14148 ± 21*
 Diastolic75 ± 880 ± 877 ± 890 ± 11*
Glucose (mmol/L)4.8 (4.5–5.1)5.0 (4.7–5.4)*4.9 (4.6–5.2)4.7 (4.4–5.1)
Insulin (μU/mL)4.2 (2.9–5.5)5.7 (4.4–10.0)*4.8 (3.3–6.7)7.7 (6.1–10.7)*
HOMA-IR1.0 (0.8–1.5)1.3 (0.8–2.0)1.1 (0.8–1.6)1.6 (1.1–2.2)*
Cholesterol (mmol/L)4.5 ± 0.94.9 ± 0.9*4.7 ± 0.95.3 ± 1.1*
Triglycerides (mmol/L)0.8 (0.7–1.1)1.1 (0.8–1.4)0.9 (0.7–1.2)1.2 (0.8–1.6)*
HDL cholesterol (mmol/L)
 Male1.5 ± 0.31.4 ± 0.31.4 ± 0.31.3 ± 0.3
 Female1.8 ± 0.31.6 ± 0.41.7 ± 0.41.8 ± 0.4
LPS (EU/mL)60 (44–80)62 (49–82)61 (44–79)49 (40–55)*
LPS/HDL ratio37 (28–51)45 (35–62)*41 (30–54)34 (26–43)*
CRP (mg/L)0.7 (0.5–1.5)1.2 (0.7–3.3)0.9 (0.5–2.0)1.7 (0.8–2.9)*
Medication (%)
 Lipid-lowering10119*
 Antihypertensive24356*
Smoking (%)14211615
  • Continuous values are presented as median (interquartile range) or as mean ± SD.

  • NDC-lean (BMI ≤ 25 kg/m2) and NDC-ow (BMI >25 kg/m2) are compared with each other; NDC-all (NDC-lean + NDC-ow) and IgAGN groups are compared with each other.

  • *P ≤ 0.001,

  • P ≤ 0.05.